Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cervical Intraepithelial Neoplasia | 7 | 2020 | 36 | 2.760 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2020 | 115 | 1.740 |
Why?
|
| Colposcopy | 6 | 2020 | 17 | 1.190 |
Why?
|
| Maternal Death | 1 | 2023 | 25 | 0.840 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2013 | 9 | 0.810 |
Why?
|
| HIV Infections | 9 | 2023 | 5097 | 0.800 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2022 | 529 | 0.720 |
Why?
|
| Vaginal Smears | 4 | 2018 | 34 | 0.710 |
Why?
|
| Pregnancy | 15 | 2024 | 1862 | 0.710 |
Why?
|
| HIV Seropositivity | 2 | 2020 | 265 | 0.650 |
Why?
|
| Stillbirth | 5 | 2024 | 83 | 0.650 |
Why?
|
| Retrospective Studies | 7 | 2023 | 799 | 0.620 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 1422 | 0.620 |
Why?
|
| Referral and Consultation | 3 | 2018 | 57 | 0.620 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2018 | 2 | 0.590 |
Why?
|
| Female | 20 | 2024 | 9103 | 0.590 |
Why?
|
| Papillomavirus Infections | 3 | 2018 | 74 | 0.580 |
Why?
|
| Papanicolaou Test | 3 | 2012 | 29 | 0.570 |
Why?
|
| South Africa | 15 | 2024 | 7596 | 0.520 |
Why?
|
| Humans | 21 | 2024 | 14537 | 0.480 |
Why?
|
| Adult | 12 | 2024 | 5913 | 0.440 |
Why?
|
| Infant, Newborn | 7 | 2024 | 1479 | 0.380 |
Why?
|
| Premature Birth | 2 | 2022 | 80 | 0.370 |
Why?
|
| Middle Aged | 6 | 2020 | 3601 | 0.320 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 231 | 0.310 |
Why?
|
| Aged | 5 | 2022 | 1740 | 0.290 |
Why?
|
| Cervix Uteri | 1 | 2008 | 22 | 0.290 |
Why?
|
| Young Adult | 6 | 2024 | 2498 | 0.280 |
Why?
|
| Cause of Death | 4 | 2024 | 221 | 0.280 |
Why?
|
| Cohort Studies | 3 | 2021 | 967 | 0.240 |
Why?
|
| Glucose Tolerance Test | 1 | 2024 | 33 | 0.230 |
Why?
|
| Blood Glucose | 1 | 2024 | 107 | 0.220 |
Why?
|
| Standard of Care | 1 | 2024 | 30 | 0.220 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 38 | 0.220 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 71 | 0.220 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 385 | 0.210 |
Why?
|
| Neural Tube Defects | 1 | 2023 | 6 | 0.210 |
Why?
|
| Adolescent | 4 | 2018 | 2985 | 0.210 |
Why?
|
| Child Mortality | 1 | 2024 | 96 | 0.210 |
Why?
|
| Hospitals | 1 | 2023 | 103 | 0.210 |
Why?
|
| Infant Mortality | 1 | 2023 | 97 | 0.200 |
Why?
|
| Infant | 3 | 2023 | 2244 | 0.200 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 15 | 0.200 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 10 | 0.200 |
Why?
|
| Cesarean Section | 1 | 2023 | 87 | 0.200 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 468 | 0.200 |
Why?
|
| Bortezomib | 1 | 2020 | 1 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 6 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 12 | 0.180 |
Why?
|
| Biopsy | 1 | 2020 | 38 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 41 | 0.170 |
Why?
|
| HIV-1 | 2 | 2020 | 1260 | 0.160 |
Why?
|
| Streptococcal Infections | 1 | 2021 | 184 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.150 |
Why?
|
| Antibodies, Bacterial | 2 | 2021 | 153 | 0.150 |
Why?
|
| Cytodiagnosis | 1 | 2018 | 2 | 0.150 |
Why?
|
| Risk Factors | 2 | 2013 | 1475 | 0.150 |
Why?
|
| Streptococcus agalactiae | 2 | 2021 | 202 | 0.140 |
Why?
|
| Gestational Age | 2 | 2019 | 80 | 0.140 |
Why?
|
| Prevalence | 2 | 2012 | 1192 | 0.130 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2015 | 40 | 0.110 |
Why?
|
| Amniotic Fluid | 1 | 2013 | 13 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 9 | 0.100 |
Why?
|
| Parity | 1 | 2013 | 19 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2012 | 133 | 0.100 |
Why?
|
| Age Factors | 1 | 2013 | 370 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 370 | 0.090 |
Why?
|
| Time Factors | 1 | 2013 | 507 | 0.090 |
Why?
|
| Autopsy | 2 | 2024 | 140 | 0.090 |
Why?
|
| Placenta | 2 | 2022 | 44 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 435 | 0.090 |
Why?
|
| Mass Screening | 1 | 2012 | 245 | 0.090 |
Why?
|
| Incidence | 1 | 2012 | 685 | 0.090 |
Why?
|
| HIV | 1 | 2013 | 380 | 0.080 |
Why?
|
| Risk | 1 | 2008 | 87 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 133 | 0.070 |
Why?
|
| Medical Audit | 1 | 2008 | 26 | 0.070 |
Why?
|
| Prenatal Care | 2 | 2019 | 147 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 188 | 0.070 |
Why?
|
| Child | 2 | 2024 | 2242 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 151 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2008 | 125 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2019 | 1160 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2008 | 889 | 0.060 |
Why?
|
| Male | 3 | 2022 | 6754 | 0.060 |
Why?
|
| ROC Curve | 1 | 2024 | 51 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 91 | 0.050 |
Why?
|
| Asia, Southeastern | 1 | 2023 | 7 | 0.050 |
Why?
|
| Ethiopia | 1 | 2023 | 18 | 0.050 |
Why?
|
| Folic Acid | 1 | 2023 | 12 | 0.050 |
Why?
|
| Birth Weight | 1 | 2022 | 80 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 117 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 101 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 39 | 0.050 |
Why?
|
| Mothers | 1 | 2023 | 195 | 0.050 |
Why?
|
| Autografts | 1 | 2020 | 1 | 0.040 |
Why?
|
| Serogroup | 1 | 2021 | 150 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 284 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 480 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 13 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.040 |
Why?
|
| Perinatal Death | 1 | 2019 | 33 | 0.040 |
Why?
|
| Placenta Diseases | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 56 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 472 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| Bacterial Capsules | 1 | 2015 | 33 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 419 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 83 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 171 | 0.030 |
Why?
|